---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-024621"
form_type: "8-K"
ticker: "CLYM"
cik: "0001768446"
company_name: "Climb Bio, Inc."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T20:48:39.135281+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Eliem Therapeutics Q3 net loss $9.7M, cash $129.6M; ETX-155 Phase 2a MDD trial to start Q1 2023

## Summary
- Net loss of $9.7M for Q3 2022 (vs. $9.6M Q3 2021); R&D expenses $4.3M, G&A $4.5M.
- Cash and marketable securities $129.6M as of Sep 30, 2022; cash runway expected to fund operations into 2025.
- ETX-155 Phase 2a MDD trial to initiate in Q1 2023 with 60-mg dose; topline data expected H2 2024.
- Kv7.2/3 program: IND-enabling safety studies for two pre-candidates expected Q1 2023; Phase 1 studies planned H1 2024.
- Phase 1 PK trial completed; selected 60-mg dose over 75-mg due to marginal additional benefit.

## SEC filing metadata
- accession: 0000950170-22-024621
- form_type: 8-K
- ticker: CLYM
- cik: 0001768446
- company_name: Climb Bio, Inc.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768446/000095017022024621/0000950170-22-024621-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768446/000095017022024621/elym-20221114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-024621
- JSON: https://secwatch.observer/filing/0000950170-22-024621.json
- Plain text: https://secwatch.observer/filing/0000950170-22-024621.txt

## Key facts
- Earnings Releases
  Climb Bio, Inc. reported the quarter ended September 30, 2022 results: net income $9.7 million.
  - Period: the quarter ended September 30, 2022
  - Net income: $9.7 million
  - Result: reported results
  source text: Net loss was $9.7 million for the three months ended September 30, 2022, compared to $9.6 million for the same period in 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1768446/000095017022024621/0000950170-22-024621-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.